Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Eximore

Ownership
Private
Therapeutic Areas
Ophthalmology
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Drug-eluting punctal plugsnano-particle technology

Eximore General Information

The company is developing a non-invasive punctal plug drug delivery system that addresses the challenges of eye drops while leveraging the high retention, tolerability, and safety of conventional punctal plugs using nano-particle technology to mold drugs into the actual plug itself.

Contact Information

Website
https://eximore.co.il/
Primary Industry
Biotech
Corporate Office
,
Israel

Drug Pipeline

EXP-LP
Phase 1/2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Eximore's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Eximore Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Eximore's complete valuation and funding history, request access »

Eximore Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals